Gold prices just lower; monthly gains on track
Investing.com -- Danaher (NYSE:DHR) shares climbed nearly 3% in premarket trading Tuesday after the life sciences firm reported better-than-expected first-quarter top and bottom line and reiterated its full-year outlook.
The company posted adjusted earnings per share (EPS) of $1.88, topping the consensus projection of $1.62. Revenue came in at $5.74 billion, also ahead of the $5.56 billion expected by analysts.
Operating profit came in at $1.27 billion, above the $1.1 billion expected.
"Revenue, earnings, and cash flow exceeded our expectations in the first quarter–highlighted by continued momentum in bioprocessing and better-than-expected respiratory demand in our molecular diagnostics business," said Rainer M. Blair, President and CEO of Danaher.
"We believe that the combination of our team’s DBS-driven execution, resilient portfolio and strong balance sheet will continue to differentiate Danaher in 2025 and beyond," he continued.
For the second quarter, the company expects non-GAAP core revenue growth in the low single digits on a year-over-year basis.
Full-year 2025 EPS is projected in the range of $7.60 to $7.75, compared to the current consensus of $7.67. Danaher also anticipates approximately 3% core revenue growth for the full year.